SCHEMBL25846222

SCHEMBL25846222

C[C@@](N)(Cc1ccc(CO)c(CO)c1)C(=O)O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 3/20 0.62
ALDH1A1 P00352 3/20 0.62
BLM P54132 2/20 0.62
KDM4E B2RXH2 2/20 0.62
POLB P06746 2/20 0.62
CYP3A4 P08684 2/20 0.62
MAPT P10636 2/20 0.62
HPGD P15428 2/20 0.62
ALOX15 P16050 2/20 0.62
HSD17B10 Q99714 2/20 0.62
TDP1 Q9NUW8 2/20 0.62
EGFR P00533 2/20 0.62
MEN1 O00255 1/20 0.62
USP2 O75604 1/20 0.62
FYN P06241 1/20 0.62
GAA P10253 1/20 0.62
APEX1 P27695 1/20 0.62
ADRA1A P35348 1/20 0.62
PTGS2 P35354 1/20 0.62
MTOR P42345 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25846211 0.87 CYP3A4 (0.46) CYP1A2ALDH1A1BLMKDM4EPOLB
SCHEMBL3872299 0.85 ALDH1A1 (0.64) CYP1A2ALDH1A1BLMKDM4EPOLB
SCHEMBL25846204 0.81 SLC6A2 (0.47) CYP1A2ALDH1A1BLMKDM4EPOLB
SCHEMBL6340509 0.79 KDM4E (0.74) CYP1A2ALDH1A1BLMKDM4EPOLB
SCHEMBL6340510 0.79 KDM4E (0.74) CYP1A2ALDH1A1BLMKDM4EPOLB
SCHEMBL17151957 0.79 CYP1A2 (0.56) CYP1A2ALDH1A1BLMKDM4EPOLB
SCHEMBL25751730 0.77 ESR1 (0.48) CYP1A2ALDH1A1BLMKDM4EPOLB
Methyldopa (Racemic) SCHEMBL196981 0.77 KDM4E (1.00) CYP1A2ALDH1A1BLMKDM4EPOLB
Methyldopa SCHEMBL30176814 0.77 KDM4E (1.00) CYP1A2ALDH1A1BLMKDM4EPOLB
Methyldopa SCHEMBL34003 0.77 KDM4E (1.00) CYP1A2ALDH1A1BLMKDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11702383-B2 Methods for producing D-α-methyldopa IMMUNOMOLECULAR THERAPEUTICS, INC. (US) 2023-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11702383-B2 Methods for producing D-α-methyldopa AMPD2, AMPD3, AMPD1 CYP1A2 330/4885ALDH1A1 371/4885BLM 4024/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.